AR134792A1 - TYK2 INHIBITOR AND ITS USE - Google Patents

TYK2 INHIBITOR AND ITS USE

Info

Publication number
AR134792A1
AR134792A1 ARP240103585A ARP240103585A AR134792A1 AR 134792 A1 AR134792 A1 AR 134792A1 AR P240103585 A ARP240103585 A AR P240103585A AR P240103585 A ARP240103585 A AR P240103585A AR 134792 A1 AR134792 A1 AR 134792A1
Authority
AR
Argentina
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
tyk2
tyk2 inhibitor
Prior art date
Application number
ARP240103585A
Other languages
Spanish (es)
Inventor
Jinyoung Park
Insoo Hwang
Heesung Chung
Jiwon Kim
Bongtae Kim
Hyejeong Kim
Chanwoo Park
keunho Lee
Yanghun Tae
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of AR134792A1 publication Critical patent/AR134792A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a un compuesto de siguiente Fórmula Química (1), un isómero óptico del mismo, un estereoisómero del mismo, un solvato del mismo, un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo, y una composición farmacéutica que incluye el mismo, y el compuesto o la sal farmacéuticamente aceptable del mismo de acuerdo con la presente divulgación puede ser utilizado eficazmente para la prevención, mejora o tratamiento de enfermedades relacionadas con TYK2.This disclosure relates to a compound of the following Chemical Formula (1), an optical isomer thereof, a stereoisomer thereof, a solvate thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same, and the compound or the pharmaceutically acceptable salt thereof according to this disclosure may be used effectively for the prevention, improvement, or treatment of TYK2-related diseases.

ARP240103585A 2023-12-20 2024-12-20 TYK2 INHIBITOR AND ITS USE AR134792A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20230187651 2023-12-20

Publications (1)

Publication Number Publication Date
AR134792A1 true AR134792A1 (en) 2026-04-01

Family

ID=96137567

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240103585A AR134792A1 (en) 2023-12-20 2024-12-20 TYK2 INHIBITOR AND ITS USE

Country Status (3)

Country Link
KR (1) KR20250096635A (en)
AR (1) AR134792A1 (en)
WO (1) WO2025135870A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106349A2 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
KR20150028999A (en) * 2012-06-27 2015-03-17 에프. 호프만-라 로슈 아게 5-azaindazole compounds and methods of use
WO2022204235A1 (en) * 2021-03-23 2022-09-29 Nido Biosciences, Inc. Bicyclic compounds as androgen receptor modulators
WO2022242697A1 (en) * 2021-05-19 2022-11-24 南京药石科技股份有限公司 Tyk2 selective inhibitor and use thereof
WO2023220046A1 (en) * 2022-05-10 2023-11-16 Biogen Ma Inc. Tyk2 inhibitors

Also Published As

Publication number Publication date
KR20250096635A (en) 2025-06-27
WO2025135870A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
CL2023000196A1 (en) Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of use thereof
CO2026005655A2 (en) Pan-kras inhibitor and its use in medicines
MX2024002538A (en) Use of ezh2 inhibitor in preparation of drug for treating t-cell lymphoma.
AR133968A1 (en) NEW COMPOUND DERIVED FROM PHTHALAZINE AS AN SOS1 INHIBITOR AND ITS USE
MX2020007947A (en) ERBB/BTK INHIBITORS.
DOP2024000146A (en) PARP7 INHIBITORS
AR127501A1 (en) PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOF
AR131639A1 (en) KIF18A INHIBITORS AND THEIR USES
CL2025000529A1 (en) Dioxoisoquinolinone derivatives, inhibitors of Ezh1 and/or Ezh2; used to treat cancer.
MX2021006724A (en) HALO-ALLYLAMINE COMPOUNDS AND USE THEREOF.
AR132764A1 (en) TYK2 INHIBITORS AND THEIR USES
DOP2025000167A (en) PRMT5–MTA INHIBITORS
AR128932A1 (en) BCL-XL INHIBITORS
AR132166A1 (en) NLRP3 INFLAMMASOME INHIBITORS AND THEIR USES
CL2025001119A1 (en) Cancer treatment methods using isoquinoline or 6-aza-quinoline derivatives
CL2024000657A1 (en) Immunomodulatory azalides
CO2025018006A2 (en) Solid forms of a macrocyclic farnesyltransferase inhibitor and formulations thereof, and methods of preparation and use of the macrocyclic compound and its solid forms
CO2025016753A2 (en) gsk3α inhibitors and methods of their use
DOP2025000235A (en) NEW COMPOUND, AND A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER OR TUMORS COMPRISING THE SAME
AR126552A1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SYSTEMIC SCLEROSIS
MX2025008207A (en) Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use
AR133788A1 (en) PARP7 INHIBITORS
MX2022005415A (en) Imidazolidinone compound, preparation method therefor and use thereof.
AR133286A1 (en) RA2S heterocyclic inhibitors of IGF-1R for the treatment of diseases
AR131842A1 (en) METHODS FOR TREATING GLIOMAS